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Abstract
Genomics datasets are increasingly useful for gaining biomedical insights, with adoption in the clinic underway.
However, multiple hurdles related to data management stand in the way of their efficient large-scale utilization.
The solution proposed is a web-based data storage hub. Having clear focus, flexibility and adaptability, InSilico DB
seamlessly connects genomics dataset repositories to state-of-the-art and free GUI and command-line data analysis
tools. The InSilico DB platform is a powerful collaborative environment, with advanced capabilities for biocuration,
dataset sharing, and dataset subsetting and combination. InSilico DB is available from https://insilicodb.org.
Rationale
Since the advent of microarrays and the recent adoption
of next-generation sequencing (NGS) genome screening
technologies, the usefulness of the resulting datasets for
biomedical progress has been increasing. For example,
these have been used for diagnosing individual tumors
and discovering subclasses of disease previously undis-
tinguishable by pathologists [1,2], paving the way
towards personalized medicine.
As new knowledge and new perspectives are applied
to published data, new insights are possible [3,4]. For
example, indexes of differentiation in the thyroid can be
derived from the reuse of public datasets [5], and gen-
eral models of disease classification built [6]. Also, gen-
ome-wide data analysis methodologies can be tested
comprehensively on a large scale [7]. Moreover, generic
datasets are provided as resources with the purpose of
being reused in the light of individual experiments, such
as compendia of genome-wide responses to drug
treatments [8], or of normal tissues, such as the Illumina
Inc. Body Map [9]. These datasets are being used for
biomedical applications such as drug repositioning [10],
elucidation of cellular functional modules [11], cancer
meta-analysis [12], the unraveling of biological factors
underlying cancer survival [13], cancer diagnosis [14,15],
and fundamental cancer research [16,17].
However, the complexity involved in managing these
datasets makes the handling of the data and the repro-
ducibility of research results very challenging [18-20].
InSilico DB aims to efficiently gather and distribute
genomic datasets to unlock their potential. This is done
by solving numerous issues around the data manage-
ment that stand in the way of the efficient and rigorous
utilization of this vast resource.
To start an analysis from available public data is diffi-
cult because the primary purpose of a repository is to
guarantee the integrity of the data, not its usability.
Indeed, prior to analysis, the raw data of genomic
experiments is normalized or genome-aligned with
sophisticated algorithms before being usable, the plat-
form features are mapped to genes, and the meta-data
(for example, patient annotations) are encoded in
spreadsheet software and mapped to the individual
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experiments. Moreover, the normalization methods, the
gene annotation, and the meta-data change in time and
must be kept up-to-date. The meta-data can also be
enriched with analysis results, such as disease classes
newly defined by subgroup discovery. Finally, the data
have to be transformed into the format accepted by the
data analysis tools before it is ready for analysis. This
process is tedious and notoriously error-prone (see, for
example, [21]). InSilico DB makes this process auto-
mated and transparent to the user.
After the dataset is first published, it is desirable to
preserve it for future use. This includes keeping track
and properly indexing past experiments for efficient
query to avoid unnecessary duplication of effort.
Another important, and quite demanding, task is to
obtain and annotate public datasets for comparison to
newly generated datasets.
Adding a layer of complexity is the interdisciplinary
nature of biomedical discovery, with bench biologists
often preferring graphical user interface (GUI) analysis
tools, such as GenePattern [22] or Integrative Genomics
Viewer (IGV) [23], and biostatisticians requiring com-
mand-line programming environments such as R/Bio-
conductor [24]. The aforementioned platforms are
tightly integrated into InSilico DB workflows, enabling
collaborative discovery.
Some of these hurdles are accentuated with more
voluminous NGS experiments. The transfer of the raw
data generated through the internet is time-consuming,
and personal computers are often not powerful enough
to process the large amounts of data involved. InSilico
DB proposes a solution to these issues by providing a
web-based central warehouse containing ready-to-use
genome-wide datasets. Detailed documentation and
tutorials are available at the InSilico DB Genomic Data-
sets Hub.
Overview of InSilico DB, browsing and searching
content
The InSilico DB Genomic Datasets Hub is populated
with data imported from multiple sources; data can
then be exported to multiple destinations in various
ready-to-analyze formats. The main features of InSilico
DB - search, browse, export and measurements group-
ing - are highlighted in Figure 1.
Available public content
InSilico DB contains a large number of microarray and
NGS datasets originating from public repositories,
NCBI Gene Expression Omnibus (GEO) [25], Short
Read Archive (SRA) [26], The Cancer Genome Atlas
project (TCGA) [27] and the Broad Institute [28]. Cur-
rently, InSilico DB supports gene expression microar-
ray Affymetrix and Illumina platforms, and Illumina
NGS platforms (for an up-to-date list of available plat-
forms, visit [29]). Clinical annotations associated with
each sample are structured using the InSilico DB bio-
curation interface, a text-structuring tool that assists
expert curators (see the ‘Clinical annotations and bio-
curation’ section below. As of August 2012, InSilico
DB contains 6,784 public datasets accounting for
214,880 samples, among which 3,382 datasets and
151,131 samples have been manually curated. Owing to
the accumulated in-house and contributed biocuration
efforts, it is possible to accurately identify 78,953 tissue
samples and 26,115 cell line samples. Table 1 gives
more detailed statistics about the most commonly
observed tissues.
InSilico DB eases the accession of large, valuable data-
sets such as the Expression Project for Oncology (ExPO)
[30], the Microarray Innovations in LEukemia (MILE)
[31,32], the Connectivity Map (C-MAP and C-MAP 2.0)
[8,33,34] or the Illumina Body Map 2.0 [9] datasets.
The entirety of the InSilico DB content provides a
standard for stand-alone genome-wide analyses with
standard software without the need of low-level data
management related tasks.
Browsing, filtering and searching InSilico DB content
Figure 1 illustrates the ‘Browse & Export’ interface. The
interface is composed of two main panels: the center
panel is a grid containing the results of the search; the
left panel contains filters to fine-tune search results
(Table 2 enumerates the available filters). Figure 1
shows the example of a query performed for the term
‘Estrogen’ resulting in the display of 153 datasets in the
‘Browse & Export’ interface. The user can then filter the
results and sort them according to any column header -
for example, the number of samples in the dataset. It is
then possible for the user to drill-down on the samples
information before selecting a dataset and exporting it
to any of the supported analysis tools.
Clinical annotations and biocuration
Online repositories of genomic datasets encourage the
use of standards for describing the biological samples.
For microarray datasets, the Minimum Information
About a Microarray Experiment (MIAME) standard has
been established [35]. This standard is particularly suc-
cessful for describing experimental protocols. However,
no standard has been accepted to describe biological
samples information. As a consequence, clinical annota-
tions are not standardized in the largest genomic data-
sets repository, GEO. A system that aims to structure
the totality of the clinical information available would
therefore necessitate a means of parsing free-form text.
InSilico DB proposes a bottom-up approach where
users can structure samples meta-information, starting
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from unstructured annotations, and define their own
structured vocabulary. Because the curation of a dataset
may differ depending on the intended application - for
example, smoking as a behavior or as a carcinogen -
InSilico DB allows one dataset to have different cura-
tions. Additionally, InSilico DB accepts batch submis-
sions from independent biocuration efforts. Batch
submissions from the Broad Institute Library of Inte-
grated Network-based Cellular Signature project [36]
and from Gemma [37,38] have been received and added
to InSilico DB.
InSilico DB proposes an interface to visualize, curate and
enrich clinical annotations of genomic datasets. Figure 2
shows the clinical annotations of the C-MAP dataset.
Information is displayed using two alternative representa-
tions, a spreadsheet view and a tree view. In the spread-







Home Search Browse & Export Samples basket Upload
2
https://insilicodb.org
Figure 1 Navigation and browse interface. (a) Navigation pane, accessible at all times by clicking on the InSilico DB logo (see below). (b) The
InSilico DB Browse & Export interface. The result after querying InSilico DB for the term ‘Estrogen’ is displayed. The main functions are indicated:
1, the InSilico DB logo is a link to access the navigation bar; 2, user information and feedback form; 3, search and find genomic datasets; 4, filter
datasets, refine search results, manage and share sample collections; 5, results panel allowing the user to drill-down into information referring to
desired datasets, and export it into supported analysis tools.
Table 1 Total number of samples, cancer samples, and













Brain 7,424 1,214 1,886
Lung 4,823 2,636 1,085
Liver 3,781 875 436
Prostate 2,717 2,250 424
Colon 2,460 1,722 254
Blood 2,247 177 648
Kidney 2,116 913 348
Ovary 2,075 1,603 109
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‘Cell Line’ or ‘Perturbagen’), and each row represents a
measurement and its associated clinical values (for exam-
ple, ‘MCF7’ or ‘estradiol’). The tree view is a condensed
representation of the clinical annotations that allows the
user to quickly identify the number of samples annotated
with given clinical factors and clinical values (the number
of samples is indicated in parentheses).
Curations can be added from comma-separated value
(CSV) files. Existing curations can be edited by using
the curation interface, accessible through the ‘Edit’
Table 2 Filters - InSilico web application
Filter Function
Dataset source Separates unpublished sample collections (such as obtained by grouping samples; My safe) from public-repository-derived
content (Public). User-contributed datasets are only visible to the owner and his/her collaborators (see the ‘A collaborative
platform’ section in the text). The Public filter can be expanded to select from the available public repositories. The InSilico filter
contains InSilico DB compiled datasets. The Community filter contains datasets shared by InSilico DB users
Curation Separates Manually curated datasets from To curate datasets. Manually curated clinical annotations have been structured and
manually curated using the InSilico DB curation interface (see the ‘Clinical annotations and biocuration’ section in the text)
Platforms Platforms are divided into two groups: gene expression microarray and next-generation sequencing. These groups can be
expanded to select specific platforms
Data pre-
processing
The data pre-processing filters are divided in microarray and next-generation sequencing groups. When raw data are available,
InSilico DB pre-processes datasets using state-of-the-art algorithms, for example, fRMA for Affymetrix arrays, and Tophat-Cufflinks
for RNA-Seq (see the ‘Genomic dataset pre-processing pipelines’ section in the text). The Original filter contains data as originally
normalized submitted by the authors
Measurement
type





4 5 6 7
8
9
Figure 2 Viewing and editing clinical annotations. Clinical annotations of the C-MAP dataset. 1, spreadsheet view with headers representing
clinical factors (for example, ‘Perturbagen’ or ‘Cell Line’), and rows representing measurements and their associated values (for example, ‘estradiol’
or ‘MCF7’). 2, Tree view condensed representation of the clinical annotations allowing fast identification of the number of samples annotated with
a given clinical factor and clinical value (number in parentheses). 3, Central panel containing a second tab with additional meta-information. For
GEO datasets, this second tab (named ‘GEO annotations’) links back to the original GEO web page dedicated to the dataset. 4, Curations upload
button. 5, Edit curations. 6, Flag a curation - for example, in case of errors in the samples’ annotations. 7, Download a curation. 8 and 9, After
clicking on the ‘Edit’ button, the spreadsheet becomes fully editable and advanced tools ease the process of structuring annotations. Here, the
curation of the C-MAP dataset is enriched with analysis results: the ‘ER status’ clinical factor is added with ‘agonist’ or ‘antagonist’ as values.
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button. To facilitate the curation of GEO studies, InSi-
lico DB has imported all GEO curations and implemen-
ted a simple interface to assist the user in structuring
this information.
The curation process is based on the observation that
the sample meta-data is amenable to a factor-value pair
description, which can be represented in a tabular form
(that is, columns correspond to factors and rows corre-
spond to values). When the factor-value pairs are avail-
able in the standard GEO format, that is, factor-value
pairs are separated by a comma character ‘,’, and the
factor is separated from the value by a colon character
‘:’ (that is, ‘key1:value1’,’key2:value2’), clicking on the
‘guess’ button of the ‘Advanced text to column tool’ will
automatically perform the curation (this tool is shown
collapsed at the bottom of the curation window shown
in the bottom of Figure 3c; please refer to the online
tutorials for a step-by-step video demonstration of this
tool [39]). In case the information is not available in the
standard GEO format, the user can proceed identically,
except that she has to define her own separators to cap-
ture and structure the information into the final tabular
form. We hope this collaborative tool will help the com-
munity structure all publicly available metadata in real-
time as it gets published.
Additionally, the curation interface enables one to
enrich existing curations to extend the set of factors
describing a dataset. Specifically, in the spreadsheet
view, each column header name in the meta-data table
accessible through the curation interface corresponds to
a factor describing the samples in a given dataset, and
each cell under the column header is the value for that
particular factor corresponding to the sample ID on a
specific row of the table (Figure 3). Spreadsheet-like
functionalities (accessible by clicking on the ‘Actions on
selected columns’ button) allow users to, (i) edit the fac-
tor name, by editing the column header, (ii) remove fac-
tors by deleting a column, or (iii) add new factors by
creating a new column or by duplicating an existing
column.
A powerful application of this capability is to enrich the
meta-data with analysis results. As an example, Figure 3
shows the process of enriching the existing C-MAP
annotations with the results from Lamb et al. [8]. While
studying the effect of estrogen receptor (ER) intracellular
signaling pathway activation, the authors assessed the
response of MCF7 cells to alpha-estradiol and beta-estra-
diol. They observed that the gene expression response of
the cells was similar to independent experiments asses-
sing the activation of the ER pathway (agonists, defined
as a high ‘connectivity score’) and opposite from cells
treated with fulverstrant, tamoxifen, and raloxifen acting
as pathway inactivators (antagonists) [8]. In agreement,
we added the ‘er status’ clinical factor and its
corresponding clinical values, ‘agonist’ and ‘antagonist’,
to the existing curation.
To ensure the traceability of the curation and repro-
ducibility of the derived results, the curation version is
uniquely identified and continuously available. The cura-
tion interface allows selection of a curation version,
including the original curation, for example, from GEO
(Figure 3a, top left corner. To assist the user in relating
their curations to the original repository, the corre-
sponding GEO web page is embedded in the side tab
(the ‘GEO annotations’ tab in Figure 3a (right tab).
Export
InSilico DB facilitates analysis by enabling a ‘one-click
export’ of genomic datasets with curated clinical annota-
tions to specific analysis platforms. Currently supported
formats are R/Bioconductor [40], GenePattern [41] and
IGV [42]. For microarray data, users can export molecu-
lar measurements per platform-specific probes or sum-
marized by genes; and choose between the normalization
provided by the original authors, or a normalization per-
formed by InSilico DB using the fRMA R/Bioconductor
package [43]. For RNA-Seq datasets, users can export
gene-expression, splice junctions, transcript expression
estimates, and differential expression results. For exome
datasets, users can export annotated variants to IGV.
The InSilico DB content is also accessible from a pro-
grammatic interface that allows for batch queries
through the R/Bioconductor package inSilicoDb [44].
To demonstrate how InSilico DB facilitates the access
to genomic content, let us consider the following case.
Suppose that a user wants to find genes correlated with
ER pathway activation. After querying for the term
‘estrogen’ in InSilico DB, she selects three datasets for
retrieval and analysis: (i) GSE20711 [45], a microarray
dataset containing 87 samples from breast cancer
patients with ER mutation status information (indicated
as ER+ or ER-); (ii) GSE27003 [46], an RNA-Seq dataset
with 8 samples from breast cancer-derived cell lines
with ER+/ER- status; and (iii) ISDB6354, a subset of the
C-MAP dataset containing the 13 MCF7 cell line sam-
ples that were treated with ER agonists or antagonists
(the ‘Grouping and sub-grouping’ section explains how
the subset is created).
For visualization and analysis, the user can export the
data to GenePattern, or to her personal computer.
Recently, GenomeSpace support has been implemented
(see the ‘Future directions’ section below). Once in Gene-
Pattern or in the user’s personal computer the data can be
visualized using IGV. Figure 4 shows an example of visua-
lization of these three datasets using IGV where expres-
sion data from the two microarray datasets can be
examined simultaneously with expression data and splicing
junctions from the RNA-Seq dataset [47]. She can then
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Figure 3 Meta-dataset creation process. Process of grouping specific selected profiles. (a) Press the green ‘+’ (plus sign) toggle button to
add samples to the ‘Samples basket’, and subsequently press the red ‘-’ (minus sign) toggle button to remove samples. (b) In the samples
basket, clinical annotations can be refined and standardized as explained in the ‘Clinical annotations and biocuration’ section. Additionally,
samples can be removed using the ‘tree view’ actions. (c) To save, the user specifies a title, a summary and the desired privacy for the new
dataset.
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determine the genes with the most statistically different
expression in the ER+/ER-phenotype using the ClassNeigh-
bors GenePattern module [48]. Alternatively, she can
retrieve the data from InSilico DB in R/Bioconductor for-
mat by executing the following code in an R console: library
(‘inSilicoDb’); breastcancer = getDataset(gse=‘GSE20711’,
gpl=‘GPL570’, norm=‘FRMA’, genes=TRUE) rnaseq = get-
Dataset(gse=‘GSE27003’,gpl=‘GPL9115’,norm=’GENEEX-
PRESSION’, genes=TRUE) cmap = getDataset(gse=
‘ISDB6354’,gpl=’GPL96’,norm=’FRMA’, genes=TRUE).
Once loaded into R/Bioconductor, the ER+/ER- sam-
ples’ annotations are used to compute the top differen-
tially expressed genes using the Limma package [49]. For
the RNA-Seq dataset, differentially expressed genes are
computed using the R/Bioconductor cummeRbund pack-
age [50]. Figure 5a shows a Venn diagram that illustrates
the intersection of the computed differentially expressed
genes (see [51] for details). Comparing the 58 intersecting
genes to the Molecular Signatures Database (MSigDB)
















Figure 4 Visualizing microarray and RNA-Seq gene expression data with IGV. Joint visualization in IGV of three datasets: two microarray
(GSE20711 and ISDB6354) and one RNA-Seq (GSE27003). The three datasets share the ER pathway activation status annotation (ER+/ER-). The top
part of the central panel displays gene expression heatmaps. The bottom view displays the splice variants for the RNA-Seq dataset. The view is
zoomed in on the locus containing an example gene, GREB1, in chromosome 2 that is regulated in the two microarray datasets.
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MSigDB web application [52] returns a list of highly sig-
nificant ER-regulated pathways (Figure 5b).
Grouping and sub-grouping
Large-scale meta-analyses, containing thousands of sam-
ples originating from various datasets from the public
domain, have shed light on the structure of the gene
‘expression space’ [6,53,54]. Analyses that group pheno-
type-specific datasets have been successful in revealing
novel gene signatures [55]. Selecting samples from large
reference datasets and grouping them into meta-datasets




















Figure 5 Comparing signatures from differentially expressed genes between ER+/ER- samples in three conditions. (a) Venn diagram
showing the intersections of the signatures of the top 500 differentially expressed genes related to the ER pathway activation status for two
microarray datasets (GSE20711 from Dedeurwaerder et al. [45], and ISDB6354 from Lamb et al. [8]) and one RNA-Seq dataset (GSE27003 from Sun
et al. [46]) (for a full list of intersecting genes, see Additional file 3). (b) Top 5 curated gene sets associated with the 64 genes at the intersections
obtained from MSigDB.
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thyroid cancer samples available from the ExPO dataset
starting from the GEO repository would require one to
download, process, curate and normalize either i) each
sample separately, repeating the process 33 times, then
reassembling them into a single dataset, or ii) the whole,
very large (13.5 GB) dataset at once and then subsetting
the resulting 33 out of 2,158 samples. To bypass this
tedious and resource-hungry process, InSilico DB allows
the user to select and group specific ‘cherry picked’
samples from one dataset, or even among various data-
sets. To select a sample, the user can click on the green
plus sign appearing to the left of unselected samples in
the curation view and, conversely, to de-select a sample,
the user can click on the red minus sign appearing to
the left of selected samples (Figure 3a). After all the
desired samples have been selected, the user can view
the selected sample collection by clicking ‘Samples bas-
ket’ (Figure 5b). The user can then (i) input a title and a
description for the sample collection, (ii) set the permis-
sion to either keep the sample collection private or to
share it with the community, and (iii) save it (Figure 5c).
From then on, the newly formed sample collection is,
for all purposes, a new dataset, but it belongs to the
user who can access it by clicking on the ‘My fafe’ filter
(Figure 1b, filter panel).
A collaborative platform
InSilico DB is a collaborative platform that allows users
to share genomic datasets. Dataset administrators can
add/remove collaborators or groups of collaborators
through a dedicated sharing interface. It is possible, as
discussed in the ‘Grouping and sub-grouping’ section to
create a new dataset by grouping samples from indepen-
dent datasets. These newly generated datasets are pri-
vate by default - that is, only the owner has access to
them. Sharing preferences and the public status of the
dataset can be changed by the owner. An owner of a
dataset can make it public to the InSilico DB commu-
nity or keep it private. A private dataset can be shared
with collaborators who can be given read-only or read-
and-write permissions. A user who has read-and-write
permissions on a dataset can edit its sharing preferences.
A tutorial to group and edit sharing permissions is avail-
able at [56]. It is also possible to share unpublished
datasets with the community by contacting InSilico DB.
The support of GUI and command-line based inter-
faces to InSilico DB allows the collaboration of compu-
tational and bench biologists. For example, a biomedical
expert can curate a given dataset using the web interface
and visualize its expression data in GenePattern and can
then in turn share this dataset with a computational col-
laborator who can perform further analyses through the
command line with R/Bioconductor.
Comparing InSilico DB with other data hubs
InSilico DB aims to greatly facilitate the use and re-use of
genomic information content. For this task, InSilico DB is
designed as a web-based data hub where datasets can be
easily inserted, maintained, annotated, pre-processed and
exported to various analysis tools or to other data hubs.
To highlight InSilico DB’s strengths and weaknesses as
well as to suggest future directions of development, it is
useful to contrast InSilico DB with other genomic data
hubs. Currently, the more mature platforms that have
been published are GEO and Gene Expression Atlas [57].
Both are web-based data hubs for genomic research and
a primary goal of each platform is to enable the re-use of
published datasets. Table 3 summarizes and compares
the features of these three platforms.
Materials and methods
Genomic dataset pre-processing pipelines
All genomic data inserted in InSilico DB are associated
with a genomic platform and a measurement type.
These values define the pipeline used to pre-process all
samples. R/Bioconductor and Python libraries are used
on the back-end for data processing. For microarray
data, background correction, normalization, and sum-
marization are performed by applying the frma function
of the fRMA R/Bioconductor package with the default
parameters. Detailed documentation on microarray gene
expression pre-processing pipelines can be found online
in the InSilico DB website (see below for the specific
URLs). For RNA-Seq data, read alignment and tran-
scripts, gene expression abundance, and differential gene
expression are computed using the Tophat-Cufflinks
and cummeRbund pipelines [58]. For exome data, InSi-
lico DB uses the genome analysis toolkit (GATK) ‘best
practice variant detection method’ pipeline [59].
Algorithm versions and parameters
InSilico DB was designed to enable biologists to effi-
ciently gather and distribute large-scale genomic datasets.
InSilico DB offers normalized data with the latest ver-
sions of state-of-the-art algorithms. When new algorithm
versions appear, their previous versions are replaced by
the most up-to-date versions in the InSilico DB pipelines
and the data are re-normalized. This process ensures
biologists always have access to data generated with the
latest stable algorithm versions. Additionally, InSilico DB
is synchronized daily with GEO to ensure the latest data-
sets are available.
To facilitate reproducibility all parameters and algo-
rithm versions necessary to recompute the pre-processed
data from the raw files are stored in the downloaded and
exported datasets. Detailed documentation on how to
access versioning and parameter information for each
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pre-processing pipeline can be found in the correspond-
ing pre-processing documentation: RNA-Seq norma-
lization pipelines are described at [60]; microarray
normalization pipelines are described at [61]; exome nor-
malization pipelines are described at [62].
Search
For searching, InSilico DB uses Sphinx [63], an open
source full-text search server, to query dataset metadata:
titles, summaries, contributors, titles and abstracts of asso-
ciated publications, clinical annotations of samples, and
curators (Additional file 1). The full-text search server pro-
vides relevance scores through a search quality index.
Backbone
As mentioned in the section ‘Overview of InSilico DB,
browsing and searching content’ above, InSilico DB con-
tains more than 200,000 genomic profiles that have
been pre-processed according to specific pipelines. Giv-
ing the fast evolution of the genomics field, its pipelines
and dependencies (for example, frma batch vectors or
the genome annotations), InSilico DB has developed an
architecture to update and re-run pre-processing pipe-
lines for all associated profiles. To facilitate the task of
pre-processing a lot of data simultaneously with mini-
mal or no manual intervention, InSilico DB uses a
workflow system developed in situ. This system, called
the ‘backbone’ of InSilico DB, handles all server jobs,
launches them on clusters by relying on a queue
mechanism and monitors them on a database. Thanks
to this ‘backbone’, pre-processing can be done on-
demand: if a user request is not available, data are auto-
matically pre-processed. After job completion, users
receive an email with a link for an automatic download/
export of the requested data (see Additional file 1 for a
detailed description of the internal setup of InSilico DB).
Architecture
InSilico DB is hosted at Universite Libre de Bruxelles
(Brussels, Belgium). It runs on a 20-node cluster with
the Linux operating system and SunGrid Engine queu-
ing system. One machine is a dedicated web-server run-
ning Apache, one machine is a dedicated MySQL server,
and one machine acts as a network attached storage
with capacity of 50 TB. The front-end is written in java-
script using ExtJS and JQuery libraries, the back-end is
implemented in Zend PHP. A schema of the database
can be found in Additional file 2.
Future directions
Although hundreds of thousands of samples are publicly
available, and several powerful analysis software
Table 3 Comparing InSilico DB with other databases
InSilico DB
functionality









Grouping New datasets created by subsetting and combining datasets
Biocuration
Collaborative Commonalizing biocuration effort through collaborative platform
Vocabulary User-defined tabular structured text Free text Ontologies &
free text




Augment Enrich curation with analysis results
Data
management
Processing raw data with latest algorithms, for example, fRMA for
microarrays, TopHat+Cufflinks for RNA-Seq
Datasets can be shared at progressive levels, including groups, and
published to the InSilico DB public repository
Data export





Output Format Multiple ready-to-use analysis-tool-compatible format (GenePattern, R/
Bioconductor and IGV compatible)
GEO-defined SOFT and text formats
Programmatic
access
InSilico Db R/Bioconductor package Through third-party GEOquery R/
Bioconductor package
SRA, Short Read Archive.
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solutions exist [22,24], the research community is facing
a chasm between these two resources. To address the
accessibility issues, the InSilico DB data hub contributes
to resolving this problem by providing a centralized
platform for the scientific community interested in
using and sharing genome-wide datasets. For NGS
experiments measuring gene expression, that is, RNA-
Seq, microarray data provide a means of comparing the
results to lower resolution but much larger published
microarray datasets. For direct genome measurement,
such as exome sequencing or whole-genome sequencing,
gene expression data can serve as a functional valida-
tion. A future goal of InSilico DB is to add support for
more genomic data types, such as single nucleotide
polymorphism arrays, whole-genome sequencing data,
methylation arrays, and microRNA platforms.
The pragmatic bottom-up approach to structuring
clinical information used by InSilico DB has already
yielded one of the largest collections of expert-reviewed
genome-wide dataset annotations. A further step would
involve relating the vocabularies defined by individual
biocurators, or biocurating efforts, to overarching, well-
defined ontologies. This would allow for the implemen-
tation of powerful mechanisms of querying InSilico DB,
making meta-analyses even easier. Fortunately, biomedi-
cal ontologies exist (for example, the Unified Medical
Language System (UMLS) [64]), as well as more general,
bioscience-oriented data-exchange formats that are cur-
rently in active development [65]. InSilico DB accepts
datasets annotated according to any standard, including
these, and will in the future include tools to aid in the
compliance to these standards. Future work will focus
on the development of tools to assist users in adhering
to a particular ontology system, or in linking their
internally defined vocabularies to community-accepted
standards. Another challenge is the identifiability of the
experimental subjects that calls for a secure means of
storing the data, sharing it with approved researchers
only, and keeping track of access to files [66]. In this
respect, the InSilico DB centralized warehousing
approach would provide for a neutral location where
data exchange can occur. Future work will thus focus
on implementing highly secure mechanisms of data
exchange.
To extend the number of supported bioinformatics
analysis tools, InSilico DB will publicly release a web
API to allow programmatic access to InSilico DB from
third party tools. A pre-release can be found at [67].
Finally, by its participation in the GenomeSpace project
[68], InSilico DB is part of a larger community-driven
effort to improve interoperability of bioinformatics soft-
ware and ultimately the usefulness of genomic data.
GenomeSpace provides a central location on the cloud
for storage of genome-wide datasets as well as generic
means for analysis tools to connect to these datasets.
InSilico DB is the first member of the GenomeSpace
ecosystem providing expert-reviewed, richly annotated
content gathered from public repositories providing a
means for the biological researcher to unlock the poten-
tial of this vast resource.
Additional material
Additional file 3: Intersections of differentially expressed genes in
three breast cancer studies.
Additional file 1: InSilico DB architecture overview.
Additional file 2: InSilico DB database schema.
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